How to take the drug Valganciclovir/Vensevir correctly

Valganciclovir is an oral anti-cytomegalovirus (CMV) infection drug. Its usage and dosage must strictly follow the physician's instructions and drug instructions to ensure efficacy and safety. The starting dose for adult patients with CMV retinitis is 900 mg twice a day for 21 days, and then adjusted to a maintenance dose of 900 mg once a day according to the condition. For organ transplant patients, drugs are used to prevent postoperative CMV infection: high-risk patients with heart and kidney and pancreas transplants can start taking 900 mg of medication once a day within 10 days after surgery and continue until 100 days after transplantation; patients with high-risk kidney transplants can continue to take it until 200 days after transplantation to cover the high-risk period of the virus.

In pediatric patients, dosage needs to be individually adjusted based on body surface area (BSA) and creatinine clearance (CrCl). Children aged 4 months to 16 years old who are at high risk for kidney transplantation should take the drug once daily, with the dosage calculated as 7 x BSA x CrCl, starting on day 10 after surgery and continuing until day 200 after transplantation. For children aged 1 month to 16 years old who are at high risk for heart transplantation, the dose is also calculated based on body surface area and creatinine clearance, and the dose is administered once a day, starting from 10 days after surgery and completing preventive treatment 100 days after transplantation.

You can take the medicine on an empty stomach or after meals, but you need to take the medicine regularly to avoid missing doses or adjust the dosage by yourself. For patients with renal insufficiency, the dosage should be adjusted under the guidance of a doctor, and blood, renal function and related indicators should be monitored regularly to prevent drug toxic reactions. Rational use of valganciclovir can not only effectively prevent or treatCMV infection, but can also significantly reduce the risk of postoperative complications.

In addition, patients should pay attention to monitoring possible side effects, such as mild gastrointestinal discomfort or hematological abnormalities, during the medication period, and communicate with their doctors in a timely manner to adjust the plan. Standardized medication and regular follow-up are crucial for transplant and immunocompromised patients. Taking valganciclovir correctly can not only ensure the efficacy, but also optimize the patient's quality of life in long-term management. It is an important part of the modern CMV prevention and treatment strategy.

Reference materials:https://go.drugbank.com/drugs/DB01610